Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stacey Silvers

Otolaryngology/Facial Plastic Surgery New York, NY Medical Doctor

NPI 1487711727 CMS profile 22373

161 Madison Ave, #11W, New York, NY 10016

Open in the dashboard

General payments

$42,441

196 records reported · program years 2019–2025

Research payments

$318,157

Paid to them · 55 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$249,058 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Stacey Silvers of New York, NY is reported in the CMS Open Payments database as having received $42,441 across 196 general payments and $318,157 in research payments paid to them. Separately, studies naming them as principal investigator received $249,058 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Otolaryngology/Facial Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,620 36
2025 Research $88,170 14
2024 General $3,284 33
2024 Research $13,058 8
2023 General $3,809 26
2023 Research $64,062 12
2022 General $2,061 29
2022 Research $90,247 10
2021 General $10,197 25
2021 Research $62,020 10
2020 General $11,969 19
2019 General $9,501 28
2019 Research $600 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stacey Silvers
  • Otolaryngology/Facial Plastic Surgery median
  • Middle half of Otolaryngology/Facial Plastic Surgery
  • National median

In program year 2025, general payments to Stacey Silvers were reported at $1,620. Among 526 Otolaryngology/Facial Plastic Surgery profiles paid that year, the median was $306 and the middle half received between $100 and $757.

Show as a table
Year Stacey Silvers Otolaryngology/Facial Plastic Surgery median Middle half National median
2019 $9,501 $237 $98–$548 $163
2020 $11,969 $118 $46–$265 $114
2021 $10,197 $179 $69–$469 $132
2022 $2,061 $212 $94–$520 $149
2023 $3,809 $225 $97–$552 $160
2024 $3,284 $285 $111–$707 $164
2025 $1,620 $306 $100–$757 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Aerin Medical Inc. $20,357 49 payments
  2. Intersect ENT, Inc. $7,619 11 payments
  3. Medical Device Business Services, Inc. $4,950 3 payments
  4. OptiNose US, Inc. $3,785 20 payments
  5. Genzyme Corporation $2,713 30 payments
  6. Regeneron Healthcare Solutions, Inc. $773 27 payments
  7. Acclarent, Inc $639 10 payments
  8. GlaxoSmithKline, LLC. $373 19 payments
  9. Spirair, Inc. $350 1 payment
  10. Integra LifeSciences Corporation $320 11 payments
  11. Other $562 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $21,831 15 payments
  2. Honoraria $12,011 4 payments
  3. Food and Beverage $7,761 173 payments
  4. Travel and Lodging $805 3 payments
  5. Education $33 1 payment
Products named General payments · program years 2019–2025
  1. VIVAER STYLUS $14,625 26 payments
  2. RHINAER STYLUS $11,025 20 payments
  3. SINUVA $6,865 2 payments
  4. TruDi Navigation System $5,075 4 payments
  5. TruDi Nav Cable $4,950 3 payments
  6. ACCLARENT NAVWIRE SINUS NAVIGATION GUIDEWIRE $4,950 3 payments
  7. TruDi Nav Suction $4,950 3 payments
  8. VivAer $4,500 4 payments
  9. RhinAer $4,500 4 payments
  10. Xhance $3,785 20 payments
  11. Other $7,243 176 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Aerin Medical Inc. $317,557 54 payments
  2. OptiNose US, Inc. $600 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

887

Median for Otolaryngology: 297

Drug cost

$61,518

Median for Otolaryngology: $6,314

Branded share of claims

2.8%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 13 $50,583
Famotidine Generic 224 $2,816
Ipratropium Bromide Generic 84 $2,323
Omeprazole Generic 173 $1,249
Gabapentin Generic 114 $933
Azelastine Hcl Generic 22 $795
Flunisolide Generic 16 $748
Fluticasone Propionate Generic 71 $631
Pantoprazole Sodium Generic 48 $430
Mometasone Furoate Generic 14 $278

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$321,644

Medicare's payments for the services billed

Medicare patients

329

Average age 74

Services billed

1,778

190 women, 139 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 50%
Ischemic heart disease 31%
Osteoporosis 22%
Diabetes 20%
Cancer 20%
Depression 19%
COPD 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $223
  • GENZYME CORPORATION $183
$406 13 —
NUCALA
  • GlaxoSmithKline, LLC. $133
$133 — —
Ryaltris
  • Hikma Pharmaceuticals USA $43
$43 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

251 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology/Facial Plastic Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record